Bone metastasis: mechanisms and therapeutic opportunities

Suva, Larry J.; Washam, Charity L.; Nicholas, Richard W.; Griffin, Robert J.

doi:10.1038/nrendo.2010.227

Cited by 350 publications

(333 citation statements)

References 116 publications

Supporting

Mentioning

319

Contrasting

Unclassified

Order By: Relevance

“…Thus, the metastatic process as well as the establishment of metastatic bone disease is unique among the different cancer entities, as are the underlying molecular mechanisms. (28)(29)(30) In the next section, we summarize the current knowledge on the role of WNT5A in the development and bone metastatic process of prostate and breast cancer and melanoma. In addition, WNT5A also plays a role in other osteotropic cancers.…”

Section: Wnt5a In Osteotropic Tumorsmentioning

confidence: 99%

WNT5A and Its Receptors in the Bone-Cancer Dialogue

Thiele

Rachner

Rauner

et al. 2016

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Wnt signaling is critical for tumorigenesis and skeletal remodeling. However, its contribution to the formation of metastatic bone lesions remains poorly defined. One major challenge of unraveling its role in cancer progression is the high complexity of Wnt signaling, which includes numerous ligands, receptors, and inhibitors, with intricate biological effects and specific signaling pathways depending on the cellular context. In this perspective, we summarize the role of the noncanonical Wnt ligand WNT5A in the development and metastatic process of osteotropic cancer entities. We focus on its tumor-suppressive function in breast cancer, tumor promoting effects in melanoma, and ambiguous role in prostate cancer, and discuss potential challenges and opportunities that may be associated with targeting Wnt signaling for cancer therapy and treatment of bone metastases.

show abstract

Section: Wnt5a In Osteotropic Tumorsmentioning

confidence: 99%

WNT5A and Its Receptors in the Bone-Cancer Dialogue

Thiele

Rachner

Rauner

et al. 2016

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…The primary malignancy that causes metastatic sclerotic bone lesions in a male is prostate cancer 1 . Given the findings of the DEXA scan, initial plan was to do a PSA test to confirm or refute primary prostate cancer; CT chest/pelvis/abdomen; and nuclear bone scan 2 .…”

Section: Investigations and Methodsmentioning

confidence: 99%

Sclerotic Bone Metastases Diagnosed on DXA

Pickard¹,

Goh²,

Kueh³

et al. 2017

EJEA

View full text Add to dashboard Cite

“…Despite the significant improvement in recent therapeutic technologies, metastatic disease is still the ultimate cause of death in prostate cancer patients (3). Therefore, understanding the underlying mechanisms of dormancy and recurrence in bone metastasis is of paramount interest for developing a effective approach to treat and prevent recurrent prostate cancer.…”

Section: So What?mentioning

confidence: 99%

BMP7 Induces Dormancy of Prostatic Tumor Stem Cell in Bone

Kobayashi¹

2011

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES ABSTRACTBone is the most common metastatic site for prostate cancer. The growth of the tumor cells in the bone is generally slow and they often become dormant until an appropriate microenviroment is established for their re-growth. The recent stem cell theory predicts that the metastatic cells are a small population of stem-like cells in the primary tumor. However, the precise mechanism of dormancy is virtually unknown, and identifying the responsible factors and understanding their underlining mechanism are crucial for developing a novel therapeutic approach. Our preliminary data indicate that (i) bone morphogenetic protein 7 (BMP7) which is secreted from bone marrow stromal cells is able to induce senescence to prostate tumor cell and (ii) this induction is mediated by activation of the tumor metastasis suppressor gene, N-myc downstream regulated gene 1 (NDRG1). These results strongly suggest that the BMP7-NDRG1axis plays a critical role in dormancy of prostate tumor cells in the bone. The overall goal of this proposal is to elucidate the mechanism of BMP7-induced dormancy in tumor stem cells and explore a possibility of using BMP7 as an anti-metastatic drug for prostate cancer.

show abstract

Bone metastasis: mechanisms and therapeutic opportunities

Cited by 350 publications

References 116 publications

WNT5A and Its Receptors in the Bone-Cancer Dialogue

WNT5A and Its Receptors in the Bone-Cancer Dialogue

Sclerotic Bone Metastases Diagnosed on DXA

BMP7 Induces Dormancy of Prostatic Tumor Stem Cell in Bone

Contact Info

Product

Resources

About